Form 4 for RMD ResMed|
Accepted 2025-11-24 00:00:00 ET · period of report 2025-11-20 · accession 0000943819-25-000170 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-24 | 2025-11-20 | RMD | Farrell Michael J. | COB, CEO, Dir | A - Grant | $0.00 | +13.6K | 473.5K | +3% | $0 | |
| 2025-11-24 | 2025-11-20 | RMD | Farrell Michael J. | COB, CEO, Dir | F - Tax | $0.00 | -7,297 | 466.2K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | ResMed Common Stock | 2025-11-20 | A | A | 13,551 | $0.00 | 473,520 | D | — | — | |
| 2 | Common | ResMed Common Stock | 2025-11-20 | F | D | 7,297 | $0.00 | 466,223 | D | — | — |